Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) gapped up before the market opened on Thursday . The stock had previously closed at $0.51, but opened at $0.54. Ampio Pharmaceuticals shares last traded at $0.61, with a volume of 44343 shares trading hands.
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) last announced its earnings results on Tuesday, August 14th. The specialty pharmaceutical company reported $0.05 earnings per share for the quarter.
Institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers bought a new stake in Ampio Pharmaceuticals during the second quarter worth about $154,000. Schwab Charles Investment Management Inc. bought a new stake in Ampio Pharmaceuticals during the second quarter worth about $326,000. Bank of New York Mellon Corp boosted its stake in Ampio Pharmaceuticals by 290.2% during the second quarter. Bank of New York Mellon Corp now owns 202,590 shares of the specialty pharmaceutical company’s stock worth $446,000 after acquiring an additional 150,664 shares in the last quarter. Courier Capital LLC boosted its stake in Ampio Pharmaceuticals by 2,032.7% during the third quarter. Courier Capital LLC now owns 304,973 shares of the specialty pharmaceutical company’s stock worth $155,000 after acquiring an additional 290,673 shares in the last quarter. Finally, Valeo Financial Advisors LLC bought a new stake in Ampio Pharmaceuticals during the second quarter worth about $155,000.
ILLEGAL ACTIVITY WARNING: “Ampio Pharmaceuticals (AMPE) Shares Gap Up to $0.54” was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.thelincolnianonline.com/2018/11/08/ampio-pharmaceuticals-ampe-shares-gap-up-to-0-54.html.
About Ampio Pharmaceuticals (NYSEAMERICAN:AMPE)
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability.
See Also: Put Option
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.